



ASX/Media Release

24 October 2019

Receipt of first R&D Tax Incentive Rebate

Melbourne, Australia; 24 October 2019: Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that the Company’s 100% owned investee company Acrux Commercial Pty Ltd has received its R&D Tax Incentive Rebate from the Australian Taxation Office of \$501,605 for the 2018/2019 financial year.

A further \$1,513,637 is expected to be received by the Company’s 100% owned subsidiary Acrux Pharma Pty Ltd during CY19.

The R&D Tax Incentive is an Australian Government program under which companies receive cash refunds for 43.5% of eligible expenditure on research and development.

For more information, please contact:

General enquiries

Michael Kotsanis
Acrux Limited
CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au

Investor enquiries

Joel Seah
Vesparum Capital

P: +61 3 8582 4800

E: acrux@vesparum.com

About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au